国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (5): 584-589.doi: 10.7518/gjkq.2018.05.015

• 综述 • 上一篇    下一篇

慢性黏膜皮肤念珠菌病的治疗进展

冯璐,孟文霞()   

  1. 南方医科大学口腔医院黏膜病科 广州 510280
  • 收稿日期:2018-03-17 修回日期:2018-06-02 出版日期:2018-09-01 发布日期:2018-09-20
  • 通讯作者: 孟文霞 E-mail:mengwx2008@fox-mail.com
  • 作者简介:冯璐,硕士,Email:fenglu200306@126.com
  • 基金资助:
    国家自然科学基金(81500850)

Therapeutic progress of chronic mucocutaneous candidiasis disease

Lu Feng,Wenxia. Meng()   

  1. Dept. of Oral Medicine, Stomatological Hospital, Southern Medical University, Guangzhou 510280, China
  • Received:2018-03-17 Revised:2018-06-02 Online:2018-09-01 Published:2018-09-20
  • Contact: Wenxia. Meng E-mail:mengwx2008@fox-mail.com
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81500850)

摘要:

慢性黏膜皮肤念珠菌病(CMCD)是一种特殊类型的念珠菌感染,被认为是免疫缺陷相关性疾病,其发病机制复杂,治疗较为棘手。常规抗真菌药物已不能满足临床上对该病的治疗需求。随着研究发展,一些新型分子制剂对CMCD的治疗表现出巨大潜力。本文回顾了目前国内外对CMCD的治疗现状及未来的发展方向,以期为临床医生提供多重选择。

关键词: 慢性黏膜皮肤念珠菌病, 治疗, 分子制剂

Abstract:

Chronic mucocutaneous candidiasis disease (CMCD) is a special type of Candida albicans infection, which is identified associated with immunodeficiency. The pathogenesis is complex and the treatment is more difficult. Conventional antifungal drugs have failed to meet the clinical demands. With the development of various treatment studies expanding, new molecular agents have shown great potential for the treatment of CMCD. This review summarizes the current status of treatment and future development of CMCD, in order to provide more information for clinicians.

Key words: chronic mucocutaneous candidiasis disease, treatment, molecular agents

中图分类号: 

  • R781.5 +4
[1] Papazian CE, Koch R , Monilial granuloma with hypo- thyroidism: report of a case treated with amphotericin B[J]. N Engl J Med, 1960,262:16-18.
doi: 10.1056/NEJM196001072620104
[2] Puel A, Picard C, Cypowyj S , et al. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines[J]. Curr Opin Immunol, 2010,22(4):467-474.
doi: 10.1016/j.coi.2010.06.009
[3] Smeekens SP , Plantinga TS, van de Veerdonk FL, et al. STAT1 hyperphosphorylation and defective IL12R/ IL23R signaling underlie defective immunity in auto- somal dominant chronic mucocutaneous candidiasis[J]. PLoS One, 2011,6(12):e29248.
doi: 10.1371/journal.pone.0029248
[4] Liu L, Okada S, Kong XF , et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis[J]. J Exp Med, 2011,208(8):1635-1648.
doi: 10.1084/jem.20110958
[5] Al Rushood M , McCusker C, Mazer B, et al. Autoso-mal dominant cases of chronic mucocutaneous can-didiasis segregates with mutations of signal transdu-cer and activator of transcription 1, but not of Toll-like receptor 3[J]. J Pediatr, 2013,163(1):277-279.
doi: 10.1016/j.jpeds.2013.02.040
[6] Martinez-Martinez L, Martinez-Saavedra MT , Fue-ntes-Prior P, et al. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis[J]. Mol Immunol, 2015,68(2 Pt C):597-605.
doi: 10.1016/j.molimm.2015.09.014
[7] Soltész B, Tóth B, Shabashova N , et al. New and re-current gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe[J]. J Med Genet, 2013,50(9):567-578.
doi: 10.1136/jmedgenet-2013-101570
[8] Dotta L, Scomodon O, Padoan R , et al. Clinical he-terogeneity of dominant chronic mucocutaneous can-didiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease[J]. Clin Immunol, 2016,164:1-9.
doi: 10.1016/j.clim.2015.12.010
[9] Yamazaki Y, Yamada M, Kawai T , et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody[J]. J Immunol, 2014,193(10):4880-4887.
doi: 10.4049/jimmunol.1401467
[10] Lorenzini T, Dotta L, Giacomelli M , et al. STAT mu- tations as program switchers: turning primary immu-nodeficiencies into autoimmune diseases[J]. J Leukoc Biol, 2017,101(1):29-38.
doi: 10.1189/jlb.5RI0516-237RR pmid: 27803128
[11] Depner M, Fuchs S, Raabe J , et al. The extended clinical phenotype of 26 patients with chronic mucocu- taneous candidiasis due to gain-of-function mutations in STAT1[J]. J Clin Immunol, 2016,36(1):73-84.
doi: 10.1007/s10875-015-0214-9
[12] Puel A, Cypowyj S, Bustamante J , et al. Chronic mu-cocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity[J]. Science, 2011,332(6025):65-68.
doi: 10.1126/science.1200439 pmid: 21350122
[13] McDonald DR . Th17 deficiency in human disease[J]. J Allergy Clin Immunol, 2012,129(6):1429-1437.
doi: 10.1016/j.jaci.2012.03.034 pmid: 3388506
[14] Petersen EA, Alling DW, Kirkpatrick CH , Treatment of chronic mucocutaneous candidiasis with ketoco-nazole: a controlled clinical trial[J]. Ann Intern Med, 1980,93(6):791-795.
doi: 10.7326/0003-4819-93-6-791
[15] Mobacken H, Moberg S , Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. A prospective 3-year trial[J]. Dermatologica, 1986,173(5):229-236.
doi: 10.1159/000249259 pmid: 3100354
[16] Ahonen P, Myllärniemi S, Kahanpää A , et al. Keto-conazole is effective against the chronic mucocuta-neous candidosis of autoimmune polyendocrinopa-thy-candidosis-ectodermal dystrophy (APECED)[J]. Acta Med Scand, 1986,220(4):333-339.
[17] Kim JH, Choi WG, Moon JY , et al. Metabolomics-assisted metabolite profiling of itraconazole in human liver preparations[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2018,1083:68-74.
doi: 10.1016/j.jchromb.2018.02.041 pmid: 29524695
[18] Jachiet M, Lanternier F, Rybojad M , et al. Posacona-zole treatment of extensive skin and nail dermato-phytosis due to autosomal recessive deficiency of CARD9[J]. JAMA Dermatol, 2015,151(2):192-194.
doi: 10.1001/jamadermatol.2014.2154
[19] 曹江, 江学维, 章成 , 等. 泊沙康唑抗侵袭性真菌感染文献计量分析[J]. 中华医院感染学杂志, 2017,27(24):5537-5540.
Cao J, Jiang XW, Zhang C , et al. Quantitative analysis of posaconazole in the treatment of invasive fungal infection[J]. Chin J Nosocomiol, 2017,27(24):5537-5540.
[20] Alves de Medeiros AK, Lodewick E, Bogaert DJ , et al. Chronic and invasive fungal infections in a family with CARD9 deficiency[J]. J Clin Immunol, 2016,36(3):204-209.
doi: 10.1007/s10875-016-0255-8 pmid: 27116191
[21] Revankar SG, Nailor MD, Sobel JD , Use of terbina-fine in rare and refractory mycoses[J]. Future Micro-biol, 2008,3(1):9-17.
doi: 10.2217/17460913.3.1.9
[22] Hu Y, Hu Y, Lu Y , et al. A case report of penile infec-tion caused by fluconazole- and terbinafine-resistant Candida albicans[J]. Mycopathologia, 2017,182(3/4):397-402.
doi: 10.1007/s11046-016-0070-z
[23] Nielsen J, Kofod-Olsen E, Spaun E , et al. A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis[J]. BMJ Case Rep, 2015, 2015: bcr2015211372.
[24] Martinez-Suarez JV, Rodriguez-Tudela JL , In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates[J]. Antimicrob Agents Chemother, 1996,40(5):1277-1279.
[25] Jayasinghe M, Schmidt S, Walker B , et al. Success-ful treatment of azoleresistant chronic mucocu-taneous candidosis with caspofungin[J]. Acta Derm Venereol, 2006,86(6):563-564.
doi: 10.2340/00015555-0165 pmid: 17106615
[26] Caínzos-Romero T, Sánchez-Trigo S, Marfil-Verchili S , et al. Treatment of chronic mucocutaneous candidia- sis, an unsolved issue. Case report and literature re-view[J]. J Clin Cell Immunol, 2017,8:501.
[27] Kirkpatrick CH , Chronic mucocutaneous candidiasis[J]. J Am Acad Dermatol, 1994,31(3 Pt 2):S14-S17.
doi: 10.1016/S0190-9622(08)81260-1
[28] Higgins E, Al Shehri T , McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal trans-ducer and activator of transcription 1 (STAT1) mutation[J]. J Allergy Clin Immunol, 2015,135(2):551-553.
doi: 10.1016/j.jaci.2014.12.1867
[29] Weinacht KG, Charbonnier LM, Alroqi F , et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 ( STAT1) gain-of-function mutation[J]. J Allergy Clin Immunol, 2017, 139(5): 1629- 1640. e2.
doi: 10.1016/j.jaci.2016.11.022
[30] Zimmerman O, Rösler B, Zerbe CS , et al. Risks of ruxolitinib in STAT1 gain-of-function-associated se- vere fungal disease[J]. Open Forum Infect Dis, 2017, 4(4): ofx202.
doi: 10.1093/ofid/ofx202 pmid: 29226168
[31] van de Veerdonk FL, Netea MG . Treatment options for chronic mucocutaneous candidiasis[J]. J Infect, 2016,72(Suppl):S56-S60.
doi: 10.1016/j.jinf.2016.04.023 pmid: 27161991
[32] Wildbaum G, Shahar E, Katz R , et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restora-tion of IL-17 secretion[J]. J Allergy Clin Immunol, 2013,132(3):761-764.
doi: 10.1016/j.jaci.2013.04.018
[33] Kullberg BJ, Oude Lashof AM, Netea MG , Design of efficacy trials of cytokines in combination with antifungal drugs[J]. Clin Infect Dis, 2004,39(Suppl 4):S218-S223.
doi: 10.1086/421960 pmid: 15546121
[34] van de Veerdonk FL, Koenen HJ, van der Velden WJ , et al. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis[J]. Immunol Lett, 2015,167(1):54-56.
doi: 10.1016/j.imlet.2015.05.008 pmid: 25999307
[35] 李璟, 梁菁, 徐婷 , 等. IL-6 -572基因多态性与侵袭性牙周炎易感性的相关性研究[J]. 口腔疾病防治, 2017,25(11):718-722.
Li J, Liang J, Xu T , et al. Relationship between inter-leukin-6 -572 gene polymorphism and aggressive periodontitis in Chinese[J]. J Prevent Treatment Sto-matol Dis, 2017,25(11):718-722.
[36] Zheng J, van de Veerdonk FL, Crossland KL , et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous can-didiasis (CMC)[J]. Eur J Immunol, 2015,45(10):2834-2846.
doi: 10.1002/eji.201445344
[37] Abaza YM, Kadia TM, Jabbour EJ , et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies[J]. Cancer, 2017,123(24):4851-4859.
doi: 10.1002/cncr.v123.24
[38] Batlevi CL, Crump M, Andreadis C , et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma[J]. Br J Haematol, 2017,178(3):434-441.
doi: 10.1111/bjh.2017.178.issue-3
[39] Hoh MC, Lin HP, Chan LL , et al. Successful alloge-neic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome[J]. Bone Marrow Transplant, 1996,18(4):797-800.
[40] Aldave JC, Cachay E, Núñez L , et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation[J]. J Clin Immunol, 2013,33(8):1273-1275.
doi: 10.1007/s10875-013-9947-5
[41] Dhalla F, Fox H, Davenport EE , et al. Chronic muco-cutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility[J]. Clin Exp Immunol, 2016,184(2):216-227.
doi: 10.1111/cei.2016.184.issue-2
[42] Koo S, Kejariwal D, Al-Shehri T , et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation[J]. United European Gastroenterol J, 2017,5(5):625-631.
doi: 10.1177/2050640616684404
[43] Sampaio EP, Hsu AP, Pechacek J , et al. Signal trans-ducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioido-mycosis and histoplasmosis[J]. J Allergy Clin Immunol, 2013,131(6):1624-1634
doi: 10.1016/j.jaci.2013.01.052
[44] Tanimura M, Dohi K, Hirayama M , et al. Recurrent inflammatory aortic aneurysms in chronic mucocuta-neous candidiasis with a gain-of-function STAT1 mu- tation[J]. Int J Cardiol, 2015,196:88-90.
doi: 10.1016/j.ijcard.2015.05.183
[1] 李继遥,郑广宁. 原发性牙根纵裂的诊治策略[J]. 国际口腔医学杂志, 2020, 47(4): 373-382.
[2] 张琳琳,杜毅. 畸形舌侧沟的治疗进展[J]. 国际口腔医学杂志, 2020, 47(4): 458-462.
[3] 张敏,万浩元. 种植体周围炎药物治疗与激光治疗的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 463-470.
[4] 吴秋月,李治邦. 药物辅助治疗种植体周围炎的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 471-477.
[5] 赵玉洁,管晓燕,李小兰,陈琦君,王倩,刘建国. 巨噬细胞极化参与正畸牙移动的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 478-483.
[6] 唐蓓,赵文俊,王虎,郑广宁,游梦. 根管超填导致下牙槽神经损伤2例[J]. 国际口腔医学杂志, 2020, 47(3): 293-296.
[7] 吴勇志,尧可,陈思宇,黄能文,王了. 多生牙及其诊断治疗[J]. 国际口腔医学杂志, 2020, 47(3): 311-317.
[8] 陈艺尹,刘俊圻,李承浩. 牙槽突裂的裂隙特点及正畸治疗对唇腭裂患者牙槽突植骨术的影响[J]. 国际口腔医学杂志, 2020, 47(3): 345-350.
[9] 于林彤,宋光泰. 铒激光在儿童口腔医学中的应用[J]. 国际口腔医学杂志, 2020, 47(3): 351-355.
[10] 田国莉,江潞,陈谦明,曾昕. 味觉异常的病因和治疗研究进展[J]. 国际口腔医学杂志, 2020, 47(3): 356-361.
[11] 陈斌,徐蓉蓉,张家鼎,闫福华. 重度牙周炎患牙的保存治疗[J]. 国际口腔医学杂志, 2020, 47(2): 125-130.
[12] 蔡潇潇. 美学区数字化种植策略与流程[J]. 国际口腔医学杂志, 2019, 46(6): 621-630.
[13] 陈东,杨征,蒋丽. 放射性口腔干燥症的评估与临床管理的研究进展[J]. 国际口腔医学杂志, 2019, 46(6): 711-717.
[14] 宋少华,莫水学. 唇腭裂患者序列治疗中的正畸治疗[J]. 国际口腔医学杂志, 2019, 46(6): 740-744.
[15] 许庆安,樊明文. 非器械根管治疗与多声波超洁净系统[J]. 国际口腔医学杂志, 2019, 46(5): 522-525.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王昆润. 修补颌骨缺损的新型生物学相容材料[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 陆加梅. 不可复性关节盘移位患者术前张口度与关节镜术后疗效的相关性[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 王昆润. 咀嚼口香糖对牙周组织微循环的影响[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 宋红. 青少年牙周炎外周血分叶核粒细胞的趋化功能[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 高卫民,李幸红. 发达国家牙医学院口腔种植学教学现状[J]. 国际口腔医学杂志, 1999, 26(06): .
[6] 侯锐. 正畸患者釉白斑损害的纵向激光荧光研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 轩东英. 不同赋形剂对氢氧化钙抗菌效果的影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[8] 房兵. 唇腭裂新生儿前颌骨矫正方法及对上颌骨生长发育的影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[9] 杨美祥. 前牙厚度在预测上下颌牙量协调性中的作用[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 赵艳丽. 手术刀、电凝、CO_2和KTP激光对大鼠舌部创口的作用[J]. 国际口腔医学杂志, 1999, 26(04): .